Halozyme Therapeutics Financials

Values in thousands	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenue	$376,708	$451,767	$354,264	$325,719
Gross Profit	267,958	349,621	281,260	261,598
EBITDA	218,250	281,076	238,383	222,903
EBIT	184,517	254,396	217,921	202,441
Net Income	150,049	-141,591	175,225	165,160
Net Change In Cash	376,708	451,767	354,264	325,719
Free Cash Flow	176,337	217,602	175,567	98,148
Cash	309,749	133,820	419,665	61,861
Basic Shares	122,875	117,672	122,331	124,158

Values in thousands	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$1,396,611	$1,015,324	$829,253	$660,116
Gross Profit	1,091,175	855,907	636,892	520,812
EBITDA	904,344	656,539	451,947	315,506
EBIT	816,293	575,227	367,091	265,865
Net Income	316,889	444,091	281,594	202,129
Net Change In Cash	1,396,611	1,015,324	829,253	660,116
Cost of Revenue				115,476
Free Cash Flow	644,588	468,368	373,277	235,300
Cash	133,820	115,850	118,370	234,195
Basic Shares	123,904	129,424	134,197	140,608